| Q48566514 | Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases |
| Q37042732 | Avoiding OHSS: Controlled Ovarian Low-Dose Stimulation in Women with PCOS. |
| Q48510192 | Combined modalities for the prevention of ovarian hyperstimulation syndrome following an excessive response to stimulation. |
| Q60046298 | Comparison of GnRH agonist and hCG for priming in vitro maturation cycles in cancer patients undergoing urgent fertility preservation |
| Q64998189 | Comparison of Oocyte Maturation Trigger Using Follicle Stimulating Hormone Plus Human Chorionic Gonadotropin versus hCG Alone in Assisted Reproduction Technology Cycles. |
| Q40151006 | Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? |
| Q48572942 | Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial. |
| Q47950058 | Day two post retrieval 1500 IUI hCG bolus, progesterone-free luteal support post GnRH agonist trigger - a proof of concept study |
| Q52608598 | Daytime Variation in Serum Progesterone During the Mid-Luteal Phase in Women Undergoing In Vitro Fertilization Treatment. |
| Q35237847 | Different gonadotropin releasing hormone agonist doses for the final oocyte maturation in high-responder patients undergoing in vitro fertilization/intra-cytoplasmic sperm injection |
| Q94572540 | ESHRE guideline: ovarian stimulation for IVF/ICSI† |
| Q48529176 | Effect of GnRHa ovulation trigger dose on follicular fluid characteristics and granulosa cell gene expression profiles |
| Q36060453 | Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy |
| Q35062457 | Fertility preservation for non-medical reasons: controversial, but increasingly common. |
| Q35934317 | Fertility preservation in reproductive-age women facing gonadotoxic treatments |
| Q55116047 | Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: A randomized, multi-center study. |
| Q33770533 | GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis |
| Q28077044 | GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article |
| Q36783410 | GnRH agonist triggering affects the kinetics of embryo development: a comparative study |
| Q38222516 | GnRH agonist triggers and their use in assisted reproductive technology: the past, the present and the future |
| Q30252505 | GnRH-agonist triggering for final oocyte maturation in GnRH-antagonist IVF cycles induces decreased LH pulse rate and amplitude in early luteal phase: a possible luteolysis mechanism |
| Q37350477 | Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial. |
| Q88990735 | Gonadotropin-releasing hormone agonist triggering of oocyte maturation in assisted reproductive technology cycles |
| Q24193015 | Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology |
| Q100523508 | Gonadotropin-releasing hormone analogs: mechanisms of action and clinical applications in female reproduction |
| Q42323243 | Grand Challenges in Reproductive Endocrinology |
| Q37425142 | Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study |
| Q33799681 | Impact of Mid-Luteal Phase GnRH Agonist Administration on Reproductive Outcomes in GnRH Agonist-Triggered Cycles: A Randomized Controlled Trial |
| Q61443510 | Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clini |
| Q48501929 | Low-dose hCG as trigger day and 35 hr later have different ovarian hyperstimulation syndrome occurrence in females undergoing In vitro fertilization: An RCT. |
| Q24186532 | Luteal phase support for assisted reproduction cycles |
| Q41645905 | Micro-dose hCG as luteal phase support without exogenous progesterone administration: mathematical modelling of the hCG concentration in circulation and initial clinical experience |
| Q59800369 | Mid-Luteal 17-OH Progesterone Levels in 614 Women Undergoing IVF-Treatment and Fresh Embryo Transfer—Daytime Variation and Impact on Live Birth Rates |
| Q37101692 | Minimal Stimulation In Vitro Fertilization: A Better Outcome. |
| Q57177405 | Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment |
| Q90597789 | Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations |
| Q26827593 | Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention |
| Q48592002 | Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone |
| Q47186641 | Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes |
| Q34009789 | Pharmaceutical options for triggering of final oocyte maturation in ART |
| Q36301761 | Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue? |
| Q26738612 | Resurgence of Minimal Stimulation In Vitro Fertilization with A Protocol Consisting of Gonadotropin Releasing Hormone-Agonist Trigger and Vitrified-Thawed Embryo Transfer |
| Q34428728 | Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation |
| Q64235722 | Synergistic drug combinations prediction by integrating pharmacological data |
| Q100519111 | Terminal differentiation of human granulosa cells as luteinization is reversed by activin-A through silencing of Jnk pathway |
| Q90176453 | The Future of Cryopreservation in Assisted Reproductive Technologies |
| Q34458877 | The Luteal Phase after GnRHa Trigger-Understanding An Enigma |
| Q38620147 | The continuum of high ovarian response: a rational approach to the management of high responder patient subgroups |
| Q55255517 | The dual trigger study: Rationale and study design of a prospective double-blind randomized clinical trial comparing pregnancy rates after co-administration of low dose hCG at the time of GnRH agonist trigger or 35 h later for the prevention of OHSS |
| Q38716011 | The high responder: a review of pathophysiology and outcomes during IVF treatment |
| Q35269025 | Timing luteal support in assisted reproductive technology: a systematic review |